The FDA gives an orphan drug designation to drug candidates that treat a disease that affects less than 200,000 persons in the United States.
The designation is designed to give financial incentives to drugmakers so that drugs for rare diseases will be developed. Those include:
- A 50% tax credit on clinical trial costs
- A break from paying Prescription Drug User Fee Act fees
- The all-important seven years of exclusive sales
Related Fool Articles
Recent Mentions on Fool.com
- Down 30%, Worth a Look
- Today's Biggest Biotech Stories: Dendreon, AbbVie, and Omeros
- BioMarin Pharmaceutical, Inc.: Is This Orphan Drug Specialist Overvalued?
- 3 Things to Watch When Isis Pharmaceuticals Reports 2013 Earnings
- Biotech Showdown: Questcor Pharmaceuticals Inc. vs. Jazz Pharmaceuticals plc
- Today's Biggest Biotech Stories: BioCryst, Verastem, and InterMune